For research use only. Not for therapeutic Use.
Enavatuzumab（Cat No.:I042231）is a monoclonal antibody designed to target the T-cell immunoglobulin mucin-3 (TIM-3) receptor, which is expressed on immune cells and plays a role in immune suppression, especially in cancer. By blocking TIM-3, enavatuzumab aims to enhance T-cell activation and promote a stronger immune response against tumors. It is being studied in clinical trials as a potential treatment for various cancers, including solid tumors and hematologic malignancies. The drug’s goal is to overcome immune evasion mechanisms in the tumor microenvironment and improve patient outcomes when combined with other immunotherapies.
| Catalog Number | I042231 |
| CAS Number | 1062149-33-0 |
| Purity | ≥95% |
